Shares of Canadian biotech, AEterna Zentaris (AEZS), traded up 14.21% today upon FDA's approval of the firm's IND application for its bladder cancer fighting drug, AEZS-108. Approximately 21 million shares exchanged hands before the closing bell. After hour trading tacked on an additional 0.96% to $2.11 per share. AEZS is backed by strong bullish momentum, amassing 68.55% gain in the past 5 days alone.
Upcoming Events:
May 13, 2010: AEZS is scheduled to announce 1Q2010 financial and operating results tomorrow before market opening and Annual Shareholder Meeting later in the day.
May 18, 2010: President and CEO, Juergen Engel, Ph.D., will present a corporate overview at the upcoming Rodman & Renshaw Annual Global Investment Conference in the Albemarie Suite of the Grosvenor House Hotel in London, U.K
June 4-8, 2010: Final results of a randomized phase II study of perifosine in combination with capecitabine (P-CAP) versus placebo plus capecitabine (CAP) in patients (pts) with second- or third-line metastatic colorectal cancer (mCRC) will be presented at the ASCO (American Society of Clinical Oncology).
No comments:
Post a Comment